Yale School of Medicine

Research Studies at Yale

Research Studies at Yale

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

For Patients For Researchers

Conditions: Schizoaffective Disorder; Schizophrenia

What is the purpose of this trial?

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.


Dates: September 2002 -
Study Status: Recruiting

Who can participate?

Ages Eligible: 18 Years - 65 Years
Gender Eligible: Both

Inclusion Criteria:

- Diagnosis of schizophrenia or schizoaffective disorder

Exclusion

- Pregnant or lactating

Sponsors: Donaghue Medical Research Foundation, National Alliance for Research on Schizophrenia and Depression, Yale University
Phase: Phase 3

First Received: September 13, 2005 
Last Updated: August 30, 2010
Clinicaltrials.gov ID: NCT00237809
Study HIC # 0301023594

Conditions: Schizoaffective Disorder; Schizophrenia

Interventions: Drug: D-serine;
Behavioral: Cognitive retraining

What is the purpose of this trial?

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.


show additional information...

Dates: September 2002 -
Study Status: Recruiting

Who can participate?

Ages Eligible: 18 Years - 65 Years
Gender Eligible: Both

Inclusion Criteria:

- Diagnosis of schizophrenia or schizoaffective disorder

Exclusion

- Pregnant or lactating


Additional Location

Connecticut

Sponsors: Donaghue Medical Research Foundation, National Alliance for Research on Schizophrenia and Depression, Yale University
Phase: Phase 3

First Received: September 13, 2005 
Last Updated: August 30, 2010
Clinicaltrials.gov ID: NCT00237809
Study HIC # 0301023594

Participate in this trial

For more information about this trial, contact:

Rajiv Radhakrishnan, MD
203-932-5711 Ext. 3921
rajiv.radhakrishnan@yale.edu


Yale Researcher

Perry, Edward Belk Jr
Principal Investigator  

HIC # 0805003779